Keywords
How to Cite
Abstract
Bone marrow (BM) involvement in neuroblastoma patients is commonly detected by cytomorphology and associated with poor outcome. Molecular techniques, flow cytometry and immunocytochemistry were offered to detect low number of tumor cells in BM due to high value of analytical sensitivity, while prognostic significance of results, obtained with these methods is unclear. PHOX2B and/or TH genes expression was selected as molecular marker of BM involvement. It was determined in 411 BM samples obtained from 75 neuroblastoma patients. 263 BM samples were taken at the time of primary diagnosis, 80 during treatment and 68 before autologous stem cells (ASC) apheresis. Prognostic significance of BM involvement was defined using 5-year (in some groups 4-year) overall (OS), event free (EFS) and progression free (PFS) survival. 24 patients (32.0%) were positive for PHOX2B and/or TH expression in the BM at the time of primary diagnosis. They had decreased survival rates: EFS achieved 0.49±0.12, OS - 0.57±0.12, PFS - 0.54±0.12, comparing with 0.75±0.07, 0.80±0.07 and 0.77±0.07, respectively, in patients with negative BM, p=0.014, p=0.029 and p=0.033. The trend to decreased OS and PFS was detected in case of minimal residual disease presence at the end of the induction chemotherapy (OS and PFS both are 0.22±0.19 vs. 0.70±0.18 and 0.43±0.22, correspondingly, p=0.121, p=0.130). Detection of PHOX2B and/or TH genes expression in the BM before ASC harvesting led to significant decreasing of EFS and OS (0.00 vs. 0.59±0.14 and 0.75±0.13, respectively, p=0.021 and p=0.016).References
Друй А.Е., Цаур Г.А., Попов А.М. и др. Исследование возможности определения экспрессии генов TH, ELAVL4 и GD2 для оценки поражения костного мозга у пациентов с нейробластомой // Вопр. онкол. - 2012. - № 4. - С. 514-520.
Avigad S., Feinberg-Gorenshtein G., Luria D. et al. Minimal residual disease in peripheral blood stem cell harvests from high-risk neuroblastoma patients // J. Pediatr. Hematol. Oncol. - 2009. - Vol. 31. - P. 22-26.
Brodeur G.M., Pritchard J., Berthold F. et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment // J. Clin. Oncol. -1993. - Vol. 11. - P. 1466-1477.
Burchill S.A., Bradbury F.M., Smith B.M. et al. Neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase mRNA // Int. J. Cancer. - 1994. - Vol. 57. - P. 671-675.
Burchill S.A., Kinsey S.E., Picton S. et al. Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma // Med. Pediatr. Oncol. - 2001. - Vol. 36. - P. 213-219.
Cheung I.Y Detection of microscopic neuroblastoma in marrow by histology, immunocytology, and reverse transcription-PCR of multiple molecular markers / I.Y Cheung D. Barber, N.K. Cheung // Clin. Cancer Res. -1998. - Vol. 4. - P. 2801-2805.
Cheung I.Y., Cheung N.K.V. Quantification of marrow disease in neuroblastoma by real-time reverse transcription-PCR // Clin. Cancer Res. - 2001. - Vol. 7. - P. 1698-1705.
Corrias M.V., Parodi S., Haupt R. et al. Detection of GD2-positive cells in bone marrow samples and survival of patients with localised neuroblastoma // Br. J. Cancer. - 2008. - Vol. 2. - P. 263-269.
Cotterill S.J., Pearson A.D.J., Pritchard J. et al. Cotterill S.J. Clinical prognostic factors in 1277 patients with neuroblastoma: results of the European Neuroblastoma Study Group ‘Survey’ 1982-1992 // Eur. J. Cancer. - 2000. - Vol. 36. - P. 901-908.
Fukuda M., Miyajima Y., Miyashita Y., Horibe K. Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: a pilot study // J. Pediatr. Hematol. Oncol. - 2001. - Vol. 1. - P. 10-13.
Handgretinger R., Leung W., Ihm K. et al. Tumour cell contamination of autologous stem cells grafts in high-risk neuroblastoma: the good news? // Br. J. Cancer. - 2003. - Vol. 12. - P. 1874-1877.
Hartmann O., Valteau-Couanet D., Vassal G. et al. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy a stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution // Bone Marrow Transplant. - 1999. - Vol. 23. - P. 789-795.
Schumacher-Kuckelkorn R., Hero B., Ernestus K., Berthold F. Lacking immunocytological GD2 expression in neuroblastoma: report of 3 cases // Pediatr. Blood Cancer. - 2005. - Vol. 45. - P. 195-201.
Shono K., Tajiri T., Fujii Y., Suita S. Clinical implications of minimal disease in the bone marrow and peripheral blood in neuroblastoma // J. Pediatr. Surg. - 2000. - Vol. 35. - P. 1415-1420.
Stutterheim J., Gerritsen A., Zappeij-Kannegieter L. et al. PHOX2B is a novel and specific marker for minimal residual disease testing in // J. Clin. Oncol. - 2008. - Vol. 26. - P. 5443-5449.
Stutterheim J., Zappeij-Kannegieter L., Versteeg R. et al. The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma // Eur. J. Cancer. - 2011. - Vol. 47. - P. 1193-1202.
Tchirkov A., Paillard C., Halle P. et al. Significance of molecular quantification of minimal residual disease in metastatic neuroblastoma // J. Hematother. Stem Cell Res. - 2003. - Vol. 12. - P. 435-442.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...